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Reply to Tarchini
To the Editor—We appreciate the
opportunity to respond to Dr. Tarchini
regarding the important questions he
poses in his letter. The following ad-
dresses each of his points in turn. First, as
has been repeatedly demonstrated,
achievement of vancomycin trough con-
centrations in the range of 15–20 mcg/
mL does not necessarily result in im-
proved outcomes (compared with lower
trough concentrations). There have been
several papers published showing just the
opposite, similar, or worse clinical out-
comes [1–3] with higher rates of neph-
rotoxicity associated with vancomycin
trough concentrations 15 mcg/mL [1–6].
Importantly, this has been demonstrated
using multivariate techniques to adjust
for severity of illness and other risk fac-
tors [4, 5]. We performed a similar
analysis using the data from the tela-
vancin studies, wherein we examined
outcome measures by vancomycin
trough category (10 mcg/mL, 10–14 mcg/
mL, and 15 mcg/mL) and found lower
clinical response rate, higher mortality,
and higher rates of nephrotoxicity in the
highest trough group [7]. Importantly,
Acute Physiology and Chronic Health
Evaluation (APACHE) scores at baseline
were also similar across the three patient
groups, and the ﬁndings held up after
adjusting for important covariates that
would predict poor outcomes. These
observations, along with the mortality
reported in the vancomycin arm of the
Assessment of Telavancin for Treatment
of Hospital-Acquired Pneumonia trials,
suggest that inadequate dosing of van-
comycin in these studies is unlikely.
In addition, it is important to note that
the support for the vancomycin trough
concentration recommendations are
graded as IIIB (moderate evidence for
support and from opinions of respected
authorities, based on clinical experience,
descriptive studies, or reports of expert
committees), which is rather soft [8].
Unfortunately, there are no adequately
controlled prospective studies to support
the recommended trough concentrations.
Finally, the studies were conducted as
registrational studies. In the recent FDA
guidance on conduct of registrational
trials, the following recommendation
was made: ‘‘The active comparator
should be an antibacterial drug at the
recommended dosage that is FDA-ap-
proved for the treatment of ‘nosocomial
pneumonia’’’ [9].
In response to Dr. Tarchini’s second
question, there were only 20 patients
(2.7% of 754 treated) who were switched
from vancomycin to an antistaphylococcal
penicillin (footnote Table 3, original re-
port) [10]. Given that the efﬁcacy and
safety outcomes of this small cohort were
similar to that of the entire vancomycin-
treated group, their data were included
with that of the larger population.
With regard to the third question, all
but 19 of 92 patients with baseline blood
cultures containing a respiratory path-
ogen had the same pathogen in res-
piratory cultures. Only 5 of these 19
patients were included in the microbio-
logically evaluable population. Identity
between the two sources was based on
genus, species, and antimicrobial sus-
ceptibility pattern. More sophisticated
techniques to determine identity were
not carried out, so it is possible that
some of these patients had other sources
for their bacteremia.
We sincerely hope that our responses
reassure the readership of the validity
and robustness of the telavancin clinical
trial data.
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